U.S. courts have long recognized that a product or process which does not literally infringe a patent can nevertheless infringe under the "doctrine of equivalents" if it is equivalent to the claimed invention. The percentage...more
9/20/2017
/ Appeals ,
Biopharmaceutical ,
CAFC ,
Doctrine of Equivalents ,
Enzo Biochem ,
Function-Way-Result Test ,
Insubstantial Differences Test ,
Mylan Pharmaceuticals ,
Patent Infringement ,
Patents ,
Pharmaceutical Patents ,
Preliminary Injunctions ,
SCOTUS